SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Enrietti Andrew | See Remarks | 2026-08-15 | Option exercise | 25134 | $0 |
| Enrietti Andrew | See Remarks | 2026-08-15 | Tax withholding | 10931 | $177K |
| Enrietti Andrew | See Remarks | 2026-08-15 | Option exercise | 999 | $0 |
| Enrietti Andrew | See Remarks | 2026-08-15 | Tax withholding | 435 | $7K |
| Campbell Paul | See Remarks | 2026-06-25 | Open-market sell 10b5-1 | 50076 | $810K |
| Le Goff Corinne | Chief Commercial Officer | 2026-04-15 | Option exercise | 39344 | $0 |
| Le Goff Corinne | Chief Commercial Officer | 2026-04-15 | Tax withholding | 17450 | $242K |
| Le Goff Corinne | Chief Commercial Officer | 2026-04-15 | Option exercise | 3644 | $0 |
| Le Goff Corinne | Chief Commercial Officer | 2026-04-15 | Tax withholding | 1617 | $22K |
| Campbell Paul | See Remarks | 2026-03-23 | Open-market sell | 21350 | $284K |
| CORNWELL W DON | Director | 2026-03-06 | Option exercise | 23660 | $0 |
| CORNWELL W DON | Director | 2026-03-06 | Option exercise | 1175 | $0 |
| Campbell Paul | See Remarks | 2026-03-06 | Option exercise | 27603 | $0 |
| Campbell Paul | See Remarks | 2026-03-06 | Tax withholding | 12088 | $171K |
| Campbell Paul | See Remarks | 2026-03-06 | Option exercise | 1371 | $0 |
| Campbell Paul | See Remarks | 2026-03-06 | Tax withholding | 601 | $9K |
| DAMELIO FRANK A | Director | 2026-03-06 | Option exercise | 25112 | $0 |
| DAMELIO FRANK A | Director | 2026-03-06 | Option exercise | 919 | $0 |
| Enrietti Andrew | See Remarks | 2026-03-06 | X | 19169 | $0 |
| Enrietti Andrew | See Remarks | 2026-03-06 | Tax withholding | 8337 | $118K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
A $2.94B goodwill impairment charge realized in 2025, combined with a ~10% workforce reduction, enterprise-wide strategic review, and a fire at the Nashik facility, signals broad operational and financial deterioration across five or more distinct themes. Near-term revenue is further pressured by the Amitiza® patent cliff in Japan, China competitive exposure, new tariff risks on pharma imports, and FDA funding instability — all newly concrete rather than hypothetical. The Biocon stake sale provides a partial offset but does not materially change the worsening trajectory.
7 company-specific · 1 eased/removed · 1 common-mode
Added specific $2.94 billion goodwill impairment charge in 2025, escalating from generic risk disclosure to concrete realized loss.
Charges to earnings resulting from acquisitions could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends or repurchase…
New disclosure of major restructuring with ~10% headcount reduction, facility closures, and multi-year cost-saving program. Substantive operational and financial risk.
Viatris’ restructuring activities may not achieve their intended goals and may present significant challenges, which could have a material adverse effect on our business, financial condition…
Added concrete example of actual facility disruption: fire at Nashik, India facility in February 2026 with temporary suspension. Escalates from hypothetical risk to realized event.
We have a limited number of manufacturing facilities and certain third-party suppliers produce a substantial portion of our API and products, some of which require a highly exacting and complex…
Enterprise-wide strategic review (EWSR) initiated in 2025 represents material escalation. New acquisition of Aculys Pharma disclosed. Expanded scope of strategic risk with new imperatives and capital commitments.
Strategic Risks We may not realize the intended benefits of, or achieve the intended goals or outlooks with respect to, our strategic initiatives and priorities, including our enterprise-wide…
Added specific new risks: healthcare exchange subsidy reductions causing insurance coverage loss and reduced pharma spending; FDA funding instability and staff departures causing regulatory delays.
Healthcare reform legislation could have a material adverse effect on our business. In recent years, there have been numerous initiatives on the federal and state levels for comprehensive reforms…
Added specific patent loss date for Amitiza® 24 μg in Japan (June 2026) and clarified China competitive pressure applies to products without patent/regulatory protection, escalating near-term revenue risk.
We face vigorous competition that threatens the commercial acceptance and pricing of our products . 31 Table of Contents The pharmaceutical industry is highly competitive. We face competition from…
Added specific 2026 product approvals pending and new inventory-demand mismatch risk, escalating operational complexity and financial exposure.
If we are unable to successfully introduce new products in a timely manner, our future revenue and profitability may be adversely affected. Our future revenues and profitability will depend, in part…
Biocon equity stake sold for $815M cash/shares, resolving prior liquidity and valuation uncertainty. Risk shifted from illiquid private equity to traded shares with market risk.
There are risks and uncertainties associated with divestitures, product rationalizations and asset sales, one or more of which could have a material adverse effect on our business, financial…
New disclosure of material tariff and trade restriction risks specific to pharmaceutical imports, APIs, and supply chain disruption with quantifiable cost and margin impacts.
The imposition of tariffs on, or other trade restrictions or domestic sourcing requirements in, the territories and countries where we, our partners, suppliers, or customers do business, as well as…
Viatris issued a press release on August 6, 2026, reporting second-quarter 2026 financial results for the period ended June 30, 2026, including total revenues of $3.8 billion, adjusted EBITDA of $1.2 billion, adjusted EPS of $0.69, and raised full-year 2026 guidance.
View raw filing on EDGAR →Viatris entered into an amended and restated term loan credit agreement on July 1, 2026, providing a ¥40,000,000,000 principal amount senior unsecured term loan facility with a three-year maturity. The facility will be used to repay prior obligations and for general corporate purposes, and includes customary covenants.
View raw filing on EDGAR →Viatris completed a public offering of €650 million in senior notes on June 17, 2026, designated for refinancing $1.675 billion of maturing 2026 Senior Notes. This material financing activity represents a significant capital structure event affecting the company's financial position and debt obligations.
View raw filing on EDGAR →Viatris entered into an underwriting agreement to issue €650 million in Senior Notes due 2033 at 4.250%, with closing expected June 17, 2026. This is a material debt issuance that would affect investor assessment of the company's capital structure and leverage, but does not fit the more specific taxonomy categories (not a dilutive equity issuance, not M&A, not a restatement or covenant breach). The disclosure is appropriately classified as other_material rather than dilutive_issuance, which applies to equity securities.
View raw filing on EDGAR →